Twyla B. Bartel, DO, MBA, FACNM
Dear ACNM Members: This month wraps up my term as the ACNM President. Please see the link below for a summary report card of many of the items we have worked on and/or initiated this year. Your board has been QUITE busy working on these, and I must say, that I have, also! I am so proud to have had the opportunity to represent and be an advocate for all of us nuclear medicine professionals. Please put time aside to read through this Spotlights issue. Thank you so very much!
Government Relations and Advocacy Corner
Erica J Cohen, DO, MPH – Committee Chair
ACNM attended the American Medical Association’s 2014 Interim Meeting in Dallas, TX, in early November. ACNM was voted on and approved to retain representation in the House of Delegates for five more years. Some of the major topics and goals identified by the AMA included repeal of the SGR, freezing ICD-10, working with CMS to ensure that the Sunshine Act encourages transparency but also contains accurate information, support of domestic and global efforts to fight the Ebola epidemic, scaling back value-based modifier, PRQS, and meaningful use penalties, facilitating multiple state licensure for telemedicine, and maintaining separation of MOC from MOL. The new ACNM Government Relations and Advocacy Committee (GRAC) is working to identify potential Resolutions to bring before the House of Delegates to strengthen our voice within the organization. Read more…
Answer to Interesting Case Nov 2014
Asim Bag, MD
Diagnosis: Recurrent Brain Tumor
Discussion: The actual diagnosis of this patient is problematic. Worsening clinical symptoms and enlargement of the nodular enhancing component of the tumor are suggestive of tumor progression. On the other hand, presentation within little over three months of completion of radiation treatment and MGMT promoter region methylated status are concerning for pseudoprogression of tumor. An FDG PET scan is helpful in this case to distinguish between these two conditions. Tumor-to-contralateral gray matter SUV ratio was 1.9, consistent with tumor recurrence as pseudoprogression typically demonstrates lower SUV value compared to the gray matter.
Reference:Oborski MJ, Laymon CM, Lieberman FS, Mountz JM. Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET. Clin Nucl Med. 2013;38(5):381-4.
Head and Neck Cancer Staging
Pareen Mehta, MD and Patrick M. Colletti, MD
Head and neck cancers represent a wide spectrum of potentially lethal malignancies involving the many different anatomic compartments extending from the skull base to the mediastinum. Most malignant tumors in these locations are histologically squamous cell carcinomas, with a small, but significant minority of cases consisting of minor salivary gland neoplasms. The major risk factor for malignancy in these locations is a history of smoking. However, alcohol abuse and HPV are also contributing factors. Read more…
Head and Neck PET/CT: Therapy Response Interpretation Criteria (‘Hopkins Criteria’)
Charles Marcus, MD and Rathan Subramaniam, MD
The Hopkins Criteria is standardized qualitative criteria (‘perceptual quantitation’) for therapy response assessment interpretation of head and neck FDG PET/CT studies for patients with Head and Neck Squamous Cell Carcinomas. The scoring system is employed for the primary tumor, right and left side neck, and for overall assessment. The intensity of FDG uptake in the internal jugular vein (IJV) and liver is used as internal reference standards for each study. The Hopkins is described in more detail on the next page. Read More…
10 Interesting articles in Head and Neck Carcinoma
Osman Saabry, MD
1. (68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma. Schartinger VH et al. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):20-4 Study with 5 patients shows Ga-68 DOTATOC PET tracer uptake in NPC.
2. Accuracy of (18)F-flurodeoxyglucose-positron emission tomography/computed tomography in the staging of newly diagnosed nasopharyngeal carcinoma: a systematic review and meta-analysis. Vellayappan BA et al. Radiol Oncol. 2014 Nov 5;48(4):331-8. Meta-analysis of 15 studies suggests that FDG-PET/CT has good accuracy in N and M staging of NPC. Read more…
2015 Fund Raising - ACNM has Launched the ACNM Annual Fund to Benefit Nuclear Medicine Residents and our Other Young Professionals in Training
ACNM is very excited about this new fundraising program! We strongly believe in our Nuclear Medicine young professionals! We will dedicate these funds primarily for their use in the areas of education, research, leadership, and professional development, and also support of our own ACNM internship. This is an awesome way to support our Nuclear Medicine community and develop our future leaders! For donations, please contact us via firstname.lastname@example.org or donate when you renew your membership either online, or by calling us. Your donations are tax-deductible. Read more...
Have you Renewed Your ACNM Membership for 2015?
Renew your membership today to access all the benefits you can only find with ACNM, including:
• Clinical Nuclear Medicine, ACNM’s Official Journal
• Scanner, ACNM’s Quarterly Newsletter
• Discounted ACNM Annual Meeting registration fees
• Online Membership Directory
• Scientific awards for Best Abstract Presentations
More membership benefits. Renew your membership online.
Alex Antoniou, MD
Several members of the NMRO board of directors will be in attendance at the annual ACNM meeting in January 22-25, 2015 in San Antonio, TX! Residents and young professionals in training will have the chance to compete for different trainee awards, and 12 abstract presenters will win a paid trip to participate in the 3rd Sino-American Exchange Program in China, May 4-9, 2015. The NMRO BOD will be meeting to discuss our future educational events, so stay tuned for the next installment of Spotlights to find out more and we hope to see you there!
Virtual Journal Club
The Nuclear Medicine Resident Organization is pleased to announce the upcoming Virtual Journal Club will be on 68Ga-PSMA PET/CT for prostate cancer. This will also be our first international virtual journal club to be streamed live from Germany. Please join us on January 12, 2015 at 2:00pm ET. This will be a good educational event and we hope to have many more. If you (or someone you know) would like to present a virtual journal club in a subject matter you are familiar with, please contact email@example.com.
|NMRO Virtual Journal Club Webinar:|
|Date & Time: January 12, 2015 (2:00pm ET)|
|Topic: 68Ga-PSMA PET/CT: A Novel Approach for Prostate Cancer Imaging|
|Presenters: Christos Sachpekidis, MD; Christos Liolios, MSc, PhD|
Interesting Case of January 2015
This month’s case was contributed by Dr. Manohar Kuruva. History: A 46 year-old female had undergone regadenosan stress myocardial perfusion imaging with 99mTc tetrofosmin. What is the diagnosis? Please respond and send your answer to firstname.lastname@example.org before 1-16-15. The winner will be announced in March issue. Click Here to access the Interesting Case - January 2015.
2015 Scientific Abstracts
Simin Dadparvar, MD, FACNM
This year ACNM had the highest abstract submission ever. It was due to joint effort of ACNM and SNMMI to invite the Nuclear Medicine Residents and Young Professionals to participate. Seventy- Five abstracts were submitted and about 80% of them were accepted and will be published in Clinical Nuclear Medicine Journal. All presenters have a chance to write their manuscripts. These will undergo an expedited review, and accepted ones will be published in CNM journal shortly after. Read more…
Simin Dadparvar, MD
Alex Antoniou, MD
Asim Bag, MD
Twyla Bartel, DO, MBA
Erica Cohen, DO, MPH
Patrick Colletti, MD
Manohar Kuruva, MD
Charles Marcus, MD
Pareen Mehta, MD
Osman Saabry, MD
Rathan Subramaniam, MD, PhD